Platform|API|Archive|Contact
Humanexa SignalsPharmaceutical Intelligence
Subscribe
Signals
Regulatory
  • FDA
  • EMA
  • MHRA
  • PMDA
  • Health Canada
Clinical
  • Phase I
  • Phase II
  • Phase III
  • Readouts
  • Enrollment Signals
Competitive
  • Pipeline Tracking
  • Company Moves
  • Asset Intelligence
  • Landscape Reports
Markets
  • Pricing
  • Access
  • Commercial
  • Launch Tracking
M&A Watch
  • Licensing
  • Acquisitions
  • Partnerships
  • Capital Raises
StrategyCatalystsPricing
Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Powered by Humanexa

Categories

  • Regulatory
  • Clinical
  • Competitive
  • Markets
  • M&A Watch
  • Strategy
  • Catalyst Tracker

Company

  • Pricing
  • Partner with us
  • Subscribe
  • Contact
  • Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

© 2026 Humanexa Signals. All rights reserved.

Intelligence powered by the Humanexa engine.

ClinicalOncologyBreast CancerOther

STARD10's Role in HER2+ Breast Cancer Progression and Lipid Metabolism

The identification of STARD10 as a key player in HER2+ breast cancer progression and lipid metabolism presents a significant opportunity for pharmaceutical companies to innovate new therapeutic strategies. This could reshape treatment paradigms and enhance competitive positioning in the oncology market.

Published: June 17, 2026
Updated: June 17, 2026
Author: Humanexa Intelligence
Therapeutic area: Oncology / Breast Cancer
Company: Roche
Asset: trastuzumab
Trial SummaryCLN

Phase III

Oncology / Breast Cancer

Status

Active

Sponsor

Roche

Signal Score

8.4

Signal assessment

Signal strength

high

Confidence level

high

Signalhigh
Confidencehigh

Strategic implication

The identification of STARD10 as a key player in HER2+ breast cancer progression and lipid metabolism presents a significant opportunity for pharmaceutical companies to innovate new therapeutic strategies. This could reshape treatment paradigms and enhance competitive positioning in the oncology market.

Why it matters

The identification of STARD10 as a key player in HER2+ breast cancer progression and lipid metabolism presents a significant opportunity for pharmaceutical companies to innovate new therapeutic strategies. This could reshape treatment paradigms and enhance competitive positioning in the oncology market.

What changed

Other

Analysis

STARD10 is implicated in the progression of HER2+ breast cancer and regulates intracellular lipid metabolism via the cAMP/PKA/CREB1 signaling pathway.

The identification of STARD10 as a key player in HER2+ breast cancer progression and lipid metabolism presents a significant opportunity for pharmaceutical companies to innovate new therapeutic strategies. This could reshape treatment paradigms and enhance competitive positioning in the oncology market.

Monitor developments in therapies targeting lipid metabolism in HER2+ breast cancer and any clinical trials involving STARD10.

Related companies & assets

Companies

  • View signals for Roche →
  • View signals for HER2+ breast cancer →
  • View signals for Oncology →

Assets

  • trastuzumab →

Sources & Humanexa intelligence

Source links

  • STARD10 promotes progression of HER2+ breast cancer and intracellular lipid metabolism via the cAMP/PKA/CREB1 signaling axis. ↗
  • STARD10's Role in HER2+ Breast Cancer Progression and Lipid Metabolism ↗

Related Humanexa pages

  • STARD10's Role in HER2+ Breast Cancer Progression and Lipid Metabolism →

Related signals

Trial SummaryCLN

Phase III

Oncology / Breast Cancer

Status

Active

Sponsor

Roche

Signal Score

8.2

Clinicalhigh signal

Study on Educational Intervention for Breast Cancer Patients' Adherence and Sexual Function

This study evaluates the impact of an educational intervention on sexual function and treatment adherence in women with breast cancer.

June 18, 2026Read signal →
Trial SummaryCLN

Phase III

Oncology / BRAF/MEK Inhibitors

Status

Initiated

Sponsor

Novartis

Signal Score

8.2

Clinicalhigh signal

Dabrafenib and Trametinib Rollover Study for Continued Patient Access

A rollover study has been initiated to provide continued access to dabrafenib and/or trametinib for patients benefiting from these treatments.

June 18, 2026Read signal →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.